

	Contd.....2			
	For the Quarter ended on		For the Period ended on	
	30.9.2010	30.9.2009	30.9.2010	30.9.2009
Standalone Information	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)
Revenue	4,481.24	4,048.23	8,687.15	8,629.89
Profit Before Tax from Ordinary activities	205.97	(356.75)	326.96	(598.13)
Profit After Tax from Ordinary activities	205.97	(353.37)	326.96	(598.13)
				(629.89)
				20,116.58
				62.67
				28.98

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 15.11.2010
- The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- The company has on 28th July, 2010 entered into a Business Transfer Agreement with Kores(fridia) Limited for sale and transfer of its Active Pharmaceutical Ingredients (API) business together with its Manufacturing facilities located at plot Nos A-88 and D-10 MIDC, Kurkumbh, Pune, Maharashtra.
- The Company has issued USD 50 Million zero coupon Foreign Currency Convertible Bonds in November-2005. No Provision have been made during the year for foreign exchange difference account and for yield to maturity (YTM) in case of Foreign Currency Convertible Bond. The bonds have become due for redemption on 09th November, 2010 and were not redeemed.
- The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- The Consolidated Financial Statement are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountant of India.
- The Company is primarily engaged in a single segment business of Manufacturing & Marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as one entity, for its various activities and is governed by similar set of risk and returns.
- There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- Statement of Assets and Liabilities.

Particulars	(Rs. In Lakhs)	
	YEAR ENDED 30.09.2010	YEAR ENDED 30.09.2009
SHAREHOLDERS' FUND:	UNAUDITED	UNAUDITED
(a) Capital	5,028.07	5,028.06
(b) Reserve and Surplus	6,312.09	6,110.49
LOAN FUNDS	38,413.09	41,043.48
Minority Interest	128.08	73.28
FIXED ASSETS	32,211.33	38,718.83
INVESTMENTS	-	-
CURRENT ASSETS, LOANS AND ADVANCES		
(A) Inventories	6,026.61	10,353.98
(B) Sundry Debtors	10,195.62	8,375.03
(C) Cash and Bank balance	2,416.19	2,552.72
(d) Other current assets		
(e) Loans and Advances	2,795.63	2,063.15
Less: Current Liabilities and Provisions		
(a) Liabilities and Provision	5,948.59	4,353.99
Deferred Tax Assets/(Liability) (Net)	(1,228.47)	(1,195.68)
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF)	20.52	47.95
PROFIT AND LOSS ACCOUNT	(3,392.50)	4,306.67



For MARKSANS PHARMA LIMITED

MARK SALLDANHA
Managing Director.